≥99% HPLCBatch testedIdentity by MS, purity by HPLC
Lot numberedCertificate filed per lot
Cold stored2 to 8 °C until dispatch
Retatrutide
10mg lyophilised powderCAS 2381089-83-2
A single-molecule GIP, GLP-1 and glucagon receptor agonist peptide, used to study incretin pharmacology and energy-balance signalling in metabolic research models.
£69.00per vial, VAT included
In stock, dispatched same day before 16:00
- Free shipping on UK orders over £20.00
- Same day dispatch on orders placed before 16:00
- Batch certificate in the COA Database
Sold for research purposes only. For in-vitro laboratory research. Not a medicine and not for human or animal consumption. Supplied to qualified individuals aged 18 and over; you confirm this at checkout.
Research overview
Retatrutide (LY3437943) is a synthetic 39-residue peptide engineered as a single molecule that acts on the GIP, GLP-1 and glucagon receptors, carrying a C20 fatty diacid side chain that gives it a long circulating half-life through albumin binding. It is used to study incretin and glucagon receptor pharmacology and energy-balance signalling in metabolic research models. Supplied at 10mg as a lyophilised powder for in-vitro laboratory research only.
Three receptors in one ligand make Retatrutide a useful tool for receptor pharmacology. In cell lines expressing the human GIP, GLP-1 or glucagon receptor, cyclic AMP accumulation assays measure potency and efficacy at each receptor and show how the balance between them compares with single and dual agonists such as semaglutide and tirzepatide.
Laboratory work also covers receptor binding and selectivity, downstream signalling in hepatocyte and adipocyte models, and analytical characterisation: identity by mass spectrometry, purity by reverse-phase HPLC, and stability of the lyophilised and reconstituted peptide. The fatty diacid side chain makes albumin-binding studies a common line of enquiry.
Research areas
- GIP, GLP-1 and glucagon receptor cAMP assays
- Receptor selectivity and potency comparisons
- Incretin signalling in cell models
- Hepatocyte and adipocyte energy metabolism in vitro
- Albumin binding and peptide stability studies
Specifications
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.3 g/mol
- Form
- lyophilised powder
- Purity
- ≥99% (HPLC)
- Also known as
- Retatrutide, LY3437943
- Supplied as
- 10mg per vial, lyophilised powder
Storage and handling
Store the lyophilised powder in a freezer, protected from moisture and light, and let the vial reach room temperature before opening. Reconstitute with an appropriate laboratory diluent, aliquot, and avoid repeated freeze and thaw.
Certificates of analysis
Retatrutide 10mg, Supplier analytical laboratory2026-10-02 · purity 99.16%
ViewEach lot of Retatrutide is released with a certificate recording identity and purity. Enter the lot number printed on your vial on the lab testing page to view it.
Questions
What is Retatrutide?
Retatrutide, also known by its development code LY3437943, is a synthetic peptide that acts on three receptors at once: GIP, GLP-1 and glucagon. It is studied in metabolic research for how that combined receptor activity shapes incretin signalling and energy balance.
Is Retatrutide a licensed medicine?
No. Retatrutide is an investigational compound and is not authorised as a medicine in the United Kingdom or elsewhere. It is supplied here strictly for in-vitro laboratory research and is not for human or animal use.
How does it differ from semaglutide and tirzepatide?
Semaglutide acts on the GLP-1 receptor alone and tirzepatide on the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity, which is why it is used as a comparator in receptor pharmacology studies.
Metabolic
Studied alongside